Radiation therapy

In the War on Cancer, Tampa General Hospital Cancer Institute Employs AI in its Newly Established Center for Precision Radiosurgery

Retrieved on: 
Thursday, January 25, 2024
Proton, Kidney, Neck, Cancer, Prostate, Brachytherapy, Neoplasm, Sarcoma, Health, Georgetown University, HDR, Movement, Brain, Liver, Bone marrow, Cancer Institute, Lung, DSM-IV codes, Tampa General Hospital, Proton therapy, Cyberknife, Radiopharmaceutical, Radiation therapy, Radiation, Stereotactic surgery, AI, Spine, TGH, Elective surgery, SRS, Patient, Federal Medical Centres, Breast cancer, Head, SBRT, Pancreas, Medical imaging

TAMPA, Fla., Jan. 25, 2024 /PRNewswire/ -- Going under the knife is taking on a new and more promising meaning at Tampa General Hospital (TGH) Cancer Institute, where doctors are using a sophisticated AI-driven tool to treat cancer.

Key Points: 
  • TAMPA, Fla., Jan. 25, 2024 /PRNewswire/ -- Going under the knife is taking on a new and more promising meaning at Tampa General Hospital (TGH) Cancer Institute , where doctors are using a sophisticated AI-driven tool to treat cancer.
  • It is capable of treating cancerous and benign tumors throughout the body, as well as neurologic disorders, in as little as 15 minutes.
  • The tool, through its speed and advanced precision, is expected to expand the capabilities of Tampa General Cancer Institute's newly established Center for Precision Radiosurgery, said Dr. Richard Tuli, professor and chair of the Department of Radiation Oncology at USF Health Morsani College of Medicine, deputy director of the TGH Cancer Institute, and director of Radiation Oncology at Tampa General.
  • Tuli joined TGH from Memorial Sloan Kettering Cancer Center in New York, N.Y.
    "It's another example of providing our patients with the best possible care across the Tampa Bay region and the state,'' he said.

The Froedtert & Medical College of Wisconsin health network selects RayStation

Retrieved on: 
Thursday, January 18, 2024
Patient, Radiation therapy, Medical college, Health, Proton therapy, Froedtert Hospital, RaySearch Laboratories, Cancer, MCW, LET, Accuray

STOCKHOLM, Jan. 18, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that the Froedtert & Medical College of Wisconsin health network, USA, has placed an order for the treatment planning system RayStation®*.

Key Points: 
  • STOCKHOLM, Jan. 18, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that the Froedtert & Medical College of Wisconsin health network, USA, has placed an order for the treatment planning system RayStation®*.
  • The Froedtert & MCW health network has purchased RayStation for photon treatments on its Elekta linear accellerators and the Accuray Radixact® treatment delivery system, as well as hyperscanning proton licenses for the health network's upcoming Mevion S250i proton therapy system.
  • The Froedtert & MCW health network offers a nationally and internationally recognized premier cancer program with six cancer centers anchored by the only academic medical center in eastern Wisconsin.
  • The Clinical Cancer Center at the health network's Froedtert Hospital campus anticipates being the first center in Wisconsin to offer proton therapy.

EQUITY-FOCUSED HEALTHCARE POLICY STRATEGIST JOINS RESPECTED NONPROFIT, BOLSTERS EFFORTS TO BREAK DOWN BARRIERS TO CANCER CARE

Retrieved on: 
Monday, January 8, 2024
Associate, Lead, Policy, Affordable Care Act, Survivor, Caregiver, Breast cancer, Research, German Health Care Reform, Congress, Society, Education, Disability, Cancer, Health equity, American Academy, Mental health, Medicare, Loneliness, Regulatory affairs, Radiation therapy, Medicaid, Patient, Social isolation, Benefit, CSC, Child, Environment, Nursing

Most recently, Ms. Sekoni was Associate Vice President of Advocacy at Healthsperien LLC, a nationally recognized healthcare policy consulting firm, where she established a new advocacy function within the firm.

Key Points: 
  • Most recently, Ms. Sekoni was Associate Vice President of Advocacy at Healthsperien LLC, a nationally recognized healthcare policy consulting firm, where she established a new advocacy function within the firm.
  • “Cancer Support Community is at the forefront of empowering and advancing the voices, experiences, and perspectives of cancer patients, survivors, and caregivers.
  • It is an honor to lead CSC’s policy and advocacy efforts and advance initiatives that ensure those voices continue to shape policymaking,” said Ms. Sekoni.
  • “My goal is for our healthcare and social system to be grounded in equity for all people impacted by a cancer diagnosis.

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Retrieved on: 
Monday, January 8, 2024
Oncology, Health, Stem Cells, Neurology, Research, Science, Biotechnology, Virus, Cell, Cancer, Distinguishing, University, Biologic, Dove Medical Press, Neuroscience, UAB Hospital, Emory University, National academy, UAB, Glioblastoma, Radiation therapy, Neuro, Nature Biotechnology, Physician, Birmingham School of Law, Engineering, Neurosurgery, Potyvirus, Harvard Medical School, Supernova, Pulmonology, Hospital, Bangladesh Technical Education Board, University of Groningen, PNAS, Pharmaceutical industry

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.

Key Points: 
  • Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.
  • “Calidi continues to expand our Scientific and Medical Advisory Board, adding leading physicians and scientists from the top cancer hospitals and research institutions in the United States,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
  • Dr. Chiocca is a faculty member at Harvard Medical School and leads a laboratory focused on developing novel genetic therapies for malignant brain tumors.
  • from the University of Tennessee and completed his residency and fellowship at UAB Hospital in Neurology and Neuro-oncology.

RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company’s Medical Advisory Board

Retrieved on: 
Thursday, December 21, 2023
Consultant, Pupil, Drug development, Physician, Georgetown University, Research, Breast, Medical director, Radiation therapy, AMD, MedStar Georgetown University Hospital, Trial of the century, Chemical engineering, College, Eye, Radiation, National academy, Medicine, University, Prostate, OTCQB, Cancer, Interim, Teaching hospital, Patient, Central nervous system, Diagnosis, NCI, Paratriathlon, Diabetes

PETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D.

Key Points: 
  • PETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D.
  • has joined the Company’s Medical Advisory Board.
  • RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies.
  • Dr. Dritschilo is the CEO and Chairman of the Board of Directors of Shuttle Pharmaceuticals Holdings, Inc.

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Retrieved on: 
Tuesday, November 28, 2023
Associate, Metastasis, Therapeutic endoscopy, Partnership, Neoplasm, Division, Death, Alpha Sigma Tau, Lung, Research, Breast, Radiation, General Hospital, Data, Pancreas, Alpha, Brain, Vulva, JGH, Endoscopy, Clinical trial, News, FRCPC, Pancreatic cancer, CA19-9, Radiation therapy, Interim, Assistant, McGill University, Translational research, Medical school, Patient, Safety, Neck

JERUSALEM, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the release of interim results from treatment of the first five patients in the Company’s safety and feasibility trial examining the use of Alpha DaRT to treat advanced pancreatic cancer, currently underway at two university hospitals in Montreal, Canada.

Key Points: 
  • Tumor stages of the treated patients ranged from stage II to stage IV, and treated tumors were located in the pancreatic head or neck.
  • With respect to primary outcome measures, the Alpha DaRT procedure was deemed technically successful in all five cases, with Alpha DaRT sources successfully inserted into the target tumor.
  • The first two patients, who had received the fewest number of Alpha DaRT sources, both died approximately three months after treatment, and the deaths were not related to Alpha DaRT treatment.
  • The study primarily examines the safety and feasibility of placing the Alpha DaRT sources in the tumor utilizing endoscopic ultrasound, and the overall safety of the procedure by measuring adverse events.

American Shared Hospital Services Enters Into Agreement to Acquire 60% Majority Interest in Three Radiation Therapy Cancer Centers in Rhode Island

Retrieved on: 
Monday, November 20, 2023
Care New England, Sales, GenesisCare, Partnership, Risk, Software, ASHS, Bankruptcy, AMS, Particle accelerator, SAN, Recurrence, Cancer, Professor, Shoe, CNE, Radiation therapy, Patient, Roger Williams Medical Center, Medical imaging

SAN FRANCISCO, CA, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ​​via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (“ASHS” or the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced that it has entered into an Investment Purchase Agreement (the “IPA”) to purchase a 60% majority equity interest in the Southern New England Regional Cancer Center, LLC and Roger Williams Radiation Therapy, LLC, both Rhode Island limited liability companies (collectively, the “Target Companies”), as well as certain payor contracts, from GenesisCare USA, Inc., a Florida corporation (the “Seller”), for a purchase price of $2.85 million. ProspectCharterCARE, LLC d/b/a Roger Williams Medical Center and the Care New England (CNE) Health System each own 20% of the Target Companies.

Key Points: 
  • The Target Companies operate three fully functional turn-key radiation therapy cancer centers in Rhode Island, and all three sites are equipped with state-of-the-art cancer treatment technology using Linear Accelerators (LINACs) and comprehensive treatment planning software.
  • The centers are all located on or adjacent to hospital campuses and include the Southern New England Regional Cancer Centers d/b/a Maddock Radiation Therapy in Warwick, RI, and d/b/a Landmark Radiation Therapy in Woonsocket, RI.
  • The third facility is the Roger Williams Cancer Center d/b/a Roger Williams Radiation Therapy in Providence, RI.
  • These patients would have had to interrupt their life-saving treatment and attempt to seek radiation therapy elsewhere.

The Inner Circle Acknowledges, Anand Kuruvilla as a Top Pinnacle Professional for his contributions to the field of Radiation Oncology

Retrieved on: 
Friday, December 22, 2023
Mentorship, Inner circle, Philosophy, Multimedia, SUNY Downstate Medical Center, APEX, Society, Education, Palliative care, American Academy, Love, Hospice, Cancer, Radiation therapy, American College, Radiation, Nursing

PALATKA, Fla., Dec. 22, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Anand Kuruvilla is acknowledged as a Top Pinnacle Professional for his contributions to the field of Radiation Oncology.

Key Points: 
  • PALATKA, Fla., Dec. 22, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Anand Kuruvilla is acknowledged as a Top Pinnacle Professional for his contributions to the field of Radiation Oncology.
  • He earned an American post-graduate degree in radiation oncology from SUNY Downstate Medical Center in New York, where he was also the chief resident during his final year.
  • Board-certified in radiation oncology, Dr. Kuruvilla focuses on and specializes in treating various adult cancers with irradiation.
  • He has been instrumental in establishing and growing the Cancer Center of Putnam, serving as the Director of Radiation Oncology since its opening in 1991.

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 14, 2023
Lung, Lutetium (177Lu) oxodotreotide, Seed, EANM, Patient, Clinical study report, Research, Radiation therapy, Marketing, Stony Brook University, UPMC Hillman Cancer Center, Medullary thyroid cancer, Growth, Congress, University, Fortis Healthcare, Pelvic exenteration, Radiation, PRRT, Toxicity, IND, GEP-NET, MTC, Melanoma, Perspective, CATX, Communication, NET, Society, ASTRO, Therapy, NETS, Wilfrid Sellars, Brain, Biology, Nuclear Medicine and Biology, Glomus tumor, NYSE, PET/CT, SPECT/CT, Clinical trial, MC1R, Prostate cancer, NIH, Survival, UPMC, GEP, Rare-earth element, Medical imaging, Pharmaceutical industry, Medical device, Cryptocurrency, Nuclear medicine, Brachytherapy

Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.

Key Points: 
  • Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.
  • Third quarter 2023 revenue was the highest since the second quarter of 2022, with a return to growth over the third quarter of 2022.
  • Total operating expenses for the quarter ended September 30, 2023 were $11.3 million, compared to $4.6 million for the same period in 2022, an increase of 144%.
  • Cash and cash equivalents as of September 30, 2023 was $18.0 million as compared to $43.9 million on December 31, 2022.

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Tuesday, November 14, 2023
NDA, Cisplatin, Disclosure, Galera, Chronic kidney disease, Annual general meeting, Superoxide dismutase, ASN, ASTRO, Food, Type, SBRT, Head, Incidence, Investment, New Drug Application, Clinical trial, American Society of Nephrology, Insurance, Patient, Workforce, Research, Radiation therapy, Death, FDA, CKD, Neoplasm, LAPC, Therapy, Manganese, Enterocyte, GRECO, Cancer, CRL, Symantec Endpoint Protection, Combination, Superoxide dismutase mimetics, Layoff, Society, HNC, Poster, Pharmaceutical industry

MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2023 and provided recent corporate updates.

Key Points: 
  • The Company is exploring potential strategic alternatives, as it is not feasible to conduct an additional trial with the Company’s current resources.
  • Research and development expenses were $6.1 million in the third quarter of 2023, compared to $8.1 million for the same period in 2022.
  • General and administrative expenses were $5.0 million in the third quarter of 2023, compared to $4.9 million for the same period in 2022.
  • As of September 30, 2023, Galera had cash, cash equivalents and short-term investments of $28.4 million.